Jussi J. Saukkonen, MD
Associate Professor
Boston University School of Medicine
Dept of Medicine
Pulmonary, Allergy, Sleep & Critical Care Medicine

MD, Thomas Jefferson University



Special Interests:

-Biomarker development for tuberculosis diagnosis and response to therapy
-mechanisms of innate (macrophage) immunity in tuberculosis.
-modulation of the macrophage response to TB by chemokines,
-effect of microbial pathogen recognition receptors on chemokine expression.

Clinical Research interests:
-Biomarker development for tuberculosis diagnosis and response to therapy
-latent tuberculosis treatment trials
-tuberculosis disease treatment trials
-multi-drug resistant tuberculosis
-extensively drug-resistant tuberculosis
-hepatotoxicity of anti-tuberculosis medications/drug safety
-inhalation technology, inhaled xenon for organ protection, “smart” ventilators


Tuberculosis Research and Initiatives:

Our TB Clinical Research Group at Boston University School of Medicine’s Pulmonary Center is engaged in multi-center consortium studies, investigator-initiated local research studies, and educational efforts locally, regionally, nationally, and internationally. Our site has been active within the Centers for Disease Control’s Tuberculosis Trials Consortium (TBTC), the largest international consortium of its type, enrolling patients in both latent and active TB treatment trials and in pharmacokinetic studies. I serve on the Core Sciences Group, the major scientific oversight committee for this consortium, the Multi-Drug Resistant (MDR) Tuberculosis Working Group, and the Biomarker Working Group. Through work on the MDR-TB WG, I am honored to be Co-PI with a great research team on TBTC USPHS Study 30 which is Linezolid for Multi-drug resistance In Tuberculosis (LiMiT) Study, USPHS Study 30. This is a randomized, controlled trial of linezolid versus placebo with both arms receiving optimized background therapy for drug-resistant TB. Within this study we will conduct a biomarker sub-study to assess serum protein s’, clinical and other variables’ ability to predict response to TB therapy. Within the TBTC Biomarker Group, we are expanding the ability of TBTC to conduct biomarker studies in all TBTC trials, an effort which has already started with TBTC Studies 29 and 30. TBTC’s biomarker effort will also include measures of hepatotoxicity. I am chairing the TBTC Hepatotoxicity Working Group, which will standardize data collection and develop initiatives for biomarker collaborations in hepatotoxicity.

Other activities from our TB Clinical Research Group include helping found and participate in RESIST-TB, an international consortium formed to conduct trial of drug resistant TB. I serve on the Scientific Advisory Committee and the Treatment Shortening Committees of RESIST-TB.

Our group concluded a study comparing hepatotoxicity and treatment completion with isoniazid for 6 months versus rifampin and pyrazinamide for two months. This study demonstrated substantially more hepatotoxicity and no improvement in treatment completion with the two month rifampin and pyrazinamide regimen, which is now no longer recommended. An outgrowth of that work was a multi-disciplinary national effort to review epidemiology, pathogenesis, and risk factors for “Hepatotoxicity of Anti-Tuberculosis Treatment”. The resulting document was adopted by the American Thoracic Society as an official statement.

We have also completed a study identifying predictors of failure to complete treatment for latent tuberculosis infection at the first clinic visit, and we are working on patient acceptance of interferon-gamma release assay results versus traditional tuberculin skin tests.

Inhalation Technology:

As Associate Program Leader for the Inhalation Technology Program at Center for Integration of Medicine and Innovative Technology (CIMIT), I am working to develop new therapies for respiratory and other diseases. This new program brings together multi-disciplinary efforts to tackle major clinic needs involving the respiratory tract, either as a site of disease in need of treatment or as a route to systemic administration of therapy for disease elsewhere in the body. A novel project to launch soon will be inhaled xenon for neuroprotection.

Clinical Interests:

My clinical interests in the outpatient arena include tuberculosis, asthma, allergy and immunology, pulmonary complications of HIV infection, COPD, interstitial fibrosis, and general pulmonary medicine.

VA Boston Healthcare System


Active Staff Privileges
Boston Medical Center
Medicine
Pulmonary, Allergy, Sleep & Critical Care Medicine



Low-Cost, Low Maintenance Mechanical Ventilator for Developing World or Mass Casualty
10/01/2010 - 05/30/2013 (PI)
Massachusetts General Hospital DOD Army Med Resrch


Working Group for Evaluation of Xenon as a Neuroprotectant in a Traumatic Brain Injury
03/01/2012 - 02/28/2013 (PI)
Massachusetts General Hospital/CIMIT


Inhalation Technology
10/01/2008 - 09/30/2011 (PI)
Massachusetts General Hospital


CIMIT Facilitation of Bio-Security Initiatives
05/23/2008 - 09/30/2011 (PI)
Massachusetts General Hospital Department of State


Chemokines in Host Response to Mycobacterial Infection
09/30/1999 - 07/31/2004 (PI)
NIH/National Heart, Lung, and Blood Institute
5 R01 HL62977 05



Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Moro RN, Sterling TR, Saukkonen J, Vernon A, Horsburgh CR, Chaisson RE, Hamilton CD, Villarino ME, Goldberg S. Factors associated with non-completion of follow-up: 33-month latent tuberculous infection treatment trial. Int J Tuberc Lung Dis. 2017 Mar 01; 21(3):286-296. PMID: 28087928; DOI: 10.5588/ijtld.16.0469;.
  2. Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA, Lienhardt C, Menzies R, Merrifield C, Narita M, O''Brien R, Peloquin CA, Raftery A, Saukkonen J, Schaaf HS, Sotgiu G, Starke JR, Migliori GB, Vernon A. Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016 Oct 01; 63(7):853-67. PMID: 27621353; DOI: 10.1093/cid/ciw566;.
  3. Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA, Lienhardt C, Menzies R, Merrifield C, Narita M, O''Brien R, Peloquin CA, Raftery A, Saukkonen J, Schaaf HS, Sotgiu G, Starke JR, Migliori GB, Vernon A. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016 Oct 01; 63(7):e147-e195. PMID: 27516382; DOI: 10.1093/cid/ciw376;.
  4. Moro RN, Borisov AS, Saukkonen J, Khan A, Sterling TR, Villarino ME, Scott NA, Shang N, Kerrigan A, Goldberg SV. Factors Associated With Noncompletion of Latent Tuberculosis Infection Treatment: Experience From the PREVENT TB Trial in the United States and Canada. Clin Infect Dis. 2016 Jun 01; 62(11):1390-1400. PMID: 26951571; DOI: 10.1093/cid/ciw126;.
  5. Jayakumar A, Vittinghoff E, Segal MR, MacKenzie WR, Johnson JL, Gitta P, Saukkonen J, Anderson J, Weiner M, Engle M, Yoon C, Kato-Maeda M, Nahid P. Serum biomarkers of treatment response within a randomized clinical trial for pulmonary tuberculosis. Tuberculosis (Edinb). 2015 Jul; 95(4):415-20. PMID: 26022314; PMCID: PMC4521594; DOI: 10.1016/j.tube.2015.04.011;.
  6. Kane M, Korn B, Saukkonen J, McDonald C, Walsh C, Waters R, McLaughlin AM, Keane J. Barriers to accepting and completing latent tuberculosis infection treatment. Ir Med J. 2013 Jul-Aug; 106(7):200-4. PMID: 24218745.
  7. Hales CM, Heilig CM, Chaisson R, Leung CC, Chang KC, Goldberg SV, Gordin F, Johnson JL, Muzanyi G, Saukkonen J, Vernon A, Villarino ME, Burman WJ. The association between symptoms and microbiologically defined response to tuberculosis treatment. Ann Am Thorac Soc. 2013 Feb; 10(1):18-25. PMID: 23509328; DOI: 10.1513/AnnalsATS.201207-038OC;.
  8. Padayatchi N, Mac Kenzie WR, Hirsch-Moverman Y, Feng PJ, Villarino E, Saukkonen J, Heilig CM, Weiner M, El-Sadr WM. Lessons from a randomised clinical trial for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2012 Dec; 16(12):1582-7. PMID: 23131255; DOI: 10.5588/ijtld.12.0315;.
  9. Goswami ND, Gadkowski LB, Piedrahita C, Bissette D, Ahearn MA, Blain ML, Østbye T, Saukkonen J, Stout JE. Predictors of latent tuberculosis treatment initiation and completion at a U.S. public health clinic: a prospective cohort study. BMC Public Health. 2012; 12:468. PMID: 22720842; PMCID: PMC3438075; DOI: 10.1186/1471-2458-12-468;.
  10. Lamunu D, Chapman KN, Nsubuga P, Muzanyi G, Mulumba Y, Mugerwa MA, Goldberg S, Bozeman L, Engle M, Saukkonen J, Mastranunzio S, Mayanja-Kizza H, Johnson JL. Reasons for non-participation in an international multicenter trial of a new drug for tuberculosis treatment. Int J Tuberc Lung Dis. 2012 Apr; 16(4):480-5. PMID: 22640513; DOI: 10.5588/ijtld.11.0434;.
Showing 10 of 33 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 32 publications over 18 distinct years, with a maximum of 4 publications in 2004 and 2012

YearPublications
19931
19951
19961
19971
19981
19991
20011
20022
20044
20063
20071
20101
20113
20124
20132
20151
20163
20171
Contact for Mentoring:


72 E. Concord St Housman (R)
Boston MA 02118
Google Map


Saukkonen's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department